Dec 01, 2021 / 06:25PM GMT
Joshua Elliott Schimmer - Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst
All right. Welcome, everyone. It's Josh Schimmer from Evercore ISI Biotech team with BioMarin. Yesterday after a really busy day at our conference, I was thinking the last thing I want to do is listen to a 3-hour R&D event from the company. But you can turn it on double speed and turn it into just 1.5 hours, and I thought it was excellent. As I really enjoyed listening to it. You covered a lot of ground and introduced some really compelling new programs. I'm going to vote this BioMarin's best R&D Day yet in terms of shifting my perception of the company.
Questions and Answers:
Joshua Elliott Schimmer - Evercore ISI Institutional Equities, Research Division - Senior MD & Equity AnalystSo I've jotted -- as I was taking notes, I was jotting down questions, there's not going to be like a great order to this. And aside from kind of following the presentations from yesterday, I'm going to start with the steroid prophylaxis commentary